Published in Curr Opin Hematol on January 01, 2006
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell (2006) 1.76
The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer (2010) 1.47
Independent component analysis: mining microarray data for fundamental human gene expression modules. J Biomed Inform (2010) 1.39
Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle (2008) 1.33
Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proc Natl Acad Sci U S A (2007) 1.29
Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol (2014) 0.96
Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP alpha). Blood Cells Mol Dis (2008) 0.92
C/EBPalpha initiates primitive myelopoiesis in pluripotent embryonic cells. Blood (2009) 0.89
Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1. Exp Hematol (2010) 0.89
Molecular Genetic Markers in Acute Myeloid Leukemia. J Clin Med (2015) 0.88
Regulation and deregulation of mRNA translation during myeloid maturation. Exp Hematol (2010) 0.88
C/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. Cancer Genet Cytogenet (2007) 0.85
PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation. Mol Cancer Res (2009) 0.84
Identification of genes expressed in the migrating primitive myeloid lineage of Xenopus laevis. Dev Dyn (2015) 0.83
Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia. J Cell Mol Med (2009) 0.83
Myeloid-derived microRNAs, miR-223, miR27a, and miR-652, are dominant players in myeloid regulation. Biomed Res Int (2014) 0.82
Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. Leukemia (2012) 0.81
CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities. Blood (2006) 0.80
CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. J Hematol Oncol (2010) 0.79
The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica (2010) 0.78
Differential effects of sumoylation on the activities of CCAAT enhancer binding protein alpha (C/EBPα) p42 versus p30 may contribute in part, to aberrant C/EBPα activity in acute leukemias. Hematol Rep (2011) 0.77
A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. J Biomol Screen (2015) 0.76
Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget (2016) 0.76
CCAAT/Enhancer-binding Protein α (C/EBPα) Is Important for Osteoclast Differentiation and Activity. J Biol Chem (2016) 0.75
The multifaceted functions of C/EBPα in normal and malignant haematopoiesis. Leukemia (2015) 0.75
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2002) 3.97
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell (2008) 2.87
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res (2005) 2.10
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood (2005) 1.59
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Leuk Lymphoma (2013) 1.46
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol (2010) 1.46
CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood (2005) 1.34
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2003) 1.26
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci U S A (2004) 1.22
Complexity of miR-223 regulation by CEBPA in human AML. Leuk Res (2009) 1.18
Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRI. Pediatr Radiol (2012) 1.18
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood (2013) 1.11
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 1.07
Cardiac systolic rotation and contraction before and after valve replacement for aortic stenosis: a myocardial tagging study using MR imaging. AJR Am J Roentgenol (2002) 1.05
Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Blood (2011) 0.88
The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients. Blood (2012) 0.85
Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med (2013) 0.83
Time course of 23Na signal intensity after myocardial infarction in humans. Magn Reson Med (2004) 0.83
Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res (2009) 0.83
Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia. J Cell Mol Med (2009) 0.83
Pneumococcal vaccination in splenectomised cancer patients. Eur J Cancer (2005) 0.83
Heterozygous deletion of the PU.1 locus in human AML. Blood (2009) 0.81
Chemotherapy is successful in sporadic late onset nemaline myopathy (SLONM) with monoclonal gammopathy. Muscle Nerve (2010) 0.79
Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis. Blood (2011) 0.79
Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency. Transfusion (2006) 0.78
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss Med Wkly (2013) 0.78
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion (2014) 0.78
Activation of the unfolded protein response in human acute myeloid leukemia. Methods Enzymol (2011) 0.77
A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation. Swiss Med Wkly (2014) 0.77
Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns. Eur J Radiol (2007) 0.77
Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia. Br J Haematol (2014) 0.76
The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential. Leuk Res (2012) 0.76
Pitfalls in the diagnosis of intravascular large B-cell lymphoma. Eur J Haematol (2013) 0.75
Lineage-specific transcription factor aberrations in AML. Cancer Treat Res (2010) 0.75
Cutaneous zygomycosis at catheter insertion site in AML-M4Eo. Ann Hematol (2006) 0.75
Magnetic resonance imaging of the heart. Przegl Lek (2002) 0.75
Omega-3 poly-unsaturated fatty acids for the prevention of severe neutropenic enterocolitis in patients with acute myeloid leukemia. Nutr Cancer (2013) 0.75
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma (2012) 0.75
Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leuk Lymphoma (2014) 0.75
Time-resolved contrast-enhanced magnetic resonance angiography of the lower extremity. Angiology (2004) 0.75